Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus BETAPEN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus BETAPEN VK.
AMPICILLIN TRIHYDRATE vs BETAPEN-VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan synthesis, leading to cell lysis.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections; up to 500 mg orally every 4 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
0.5-1 hour in patients with normal renal function; prolonged to 7-10 hours with creatinine clearance <10 mL/min.
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Renal excretion accounts for 20-40% of the dose as unchanged drug via tubular secretion and glomerular filtration; biliary/fecal excretion is minimal (<10%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic